Objective: Asymptomatic peripheral arterial occlusive disease (PAOD) is a common atherosclerotic disorder among the elderly population. Scarce data are available on the risk of nonfatal and fatal cardiovascular diseases in these subjects. We investigated cardiovascular morbidity and mortality of asymptomatic PAOD subjects.
Introduction
Prevention of atherosclerotic diseases associated with high morbidity and mortality, like coronary heart disease and cerebrovascular disease, are main goals of public health policy in industrialized countries. Therefore, identification of high-risk groups is relevant for implementation of preventive measures.
Peripheral arterial occlusive disease (PAOD) is rarely fatal. The majority of PAOD subjects are asymptomatic and of older age [1, 2] . Intermittent claudication (IC), the most common symptomatic manifestation and PAOD, has a relatively benign course as far as the extremities are concerned [3] . Only a small minority develops critical ischemia, justifying specialist intervention [3] . Cross-sectional studies, however, show that almost half of all PAOD subjects seem to have some clinical evidence of coronary heart disease or cerebrovascular disease [3] [4] [5] . Few follow-up studies on PAOD have described subsequent cardiovascular morbidity, especially in asymptomatic subjects [6, 7] . More evidence exists on the increased risk for mortality in claudicants. Symptomatic PAOD is consistently associated with an increased risk for atherosclerotic death [3] . Scarce data are available on mortality of asymptomatic PAOD. The relative risk (RR) of death seems to be higher in asymptomatic subjects compared with the non-PAOD population [3] . Data on gender disparities for adverse outcome are also scanty. Cardiovascular morbidity rates seem higher in women with PAOD, whereas male PAOD subjects seem more at risk for cardiovascular death [3] .
The aim of our longitudinal study was to describe the cardiovascular morbidity and mortality of asymptomatic PAOD subjects after 7 years of follow-up. In addition, we investigated possible gender differences in outcome.
Methods

Study population
The Limburg PAOD Study started in 1988 in collaboration with 18 general practice centers. The study methods have been extensively described elsewhere [1, 8] . The sampling frame for the study population consisted of 26,620 subjects, aged 40-78 years, registered in the collaborating general practices. Every citizen in the Netherlands is registered in a general practice. Therefore, the practice population of a general practice is a segment of the general population. A postal screening questionnaire with five questions on pain on walking and risk factors possibly relevant for PAOD was sent to these subjects. The responders (n ϭ 23,004, 86.4% of the sampling frame; no differences between responders and nonresponders with regard to age and gender distribution) were then categorized to a "prior risk score" between 0 and 5. Through a stratified sampling procedure, 5301 subjects, representing all parts of the clinical spectrum relevant to general practice (i.e., from subjects with neither complaints nor risk factors to patients with complaints and all risk factors) were invited to participate in the study. From these, 3649 subjects (response rate 68.9%) agreed to participate in the study (mean age 59 years, 53% female). No statistically significant differences with regard to age and gender were found between participants and nonparticipants.
The study was approved by the Medical Ethics Committee of the University Hospital Maastricht.
Baseline measurements and definitions
With a self-administered questionnaire, data were collected regarding age, gender, possible IC symptoms, and current and former smoking habits. In addition, each participant underwent a physical examination, including the measurement of the ankle-brachial pressure index (ABPI) in both legs. The ABPI was measured by trained practice assistants, using a pocket Doppler device (Huntleigh Mini Dopplex D500 8 Mhz; Huntleigh Healthcare Ltd., Luton, Bedfordshire, United Kingdom) and a sphygmomanometer. Systolic pressures were recorded on both arms and ankles (posterior tibial artery or dorsalis pedis artery) with the subject lying in supine position. The ABPIs were calculated as the ratio of each ankle systolic blood pressure to the highest arm systolic blood pressure. Inter-observer and intra-observer variability for the Doppler measurements have shown to be acceptable [9, 10] .
PAOD was considered present when participants twice had an ABPI Ͻ 0.95 for at least one leg, measured with a week interval. IC was defined as pain in the calf while walking that disappeared when standing still and was not present when resting (typical IC) [11] . Other complaints involving the calf and complaints involving the foot, thigh, or buttock showing this ischemic pattern were included in the definition of atypical IC [1, 7] . Asymptomatic PAOD was defined as an ABPI Ͻ 0.95 without intermittent claudication symptoms. Symptomatic PAOD was defined as an ABPI Ͻ 0.95 with intermittent claudication symptoms [1] .
Relevant data on the presence of hypertension (guideline: five instances of diastolic pressure 95-104 mm Hg or three instances of diastolic pressure у105 mm Hg), hypercholesterolemia (guideline: mean of three measurements у6.5 mmol/L), and diabetes mellitus (guideline: typical complaints and one instance of abnormal serum glucose [fasting у6.7 mmol/L, 2hr postprandial у11.1 mmol/ L] or two instances of abnormal serum glucose) were collected from the patient's medical record. Data on the presence of coronary heart disease and cerebrovascular disease were also collected from the participants' medical records.
Ascertainment of nonfatal cardiovascular events during the follow-up period
The participants' medical records were used to collect information on end points. For nonfatal cardiovascular events, the collaborating physicians collected data on the following end points according to a specific criteria list: minor stroke, stroke, angina pectoris, silent or manifest myocardial infarction (MI), congestive heart failure, and abdominal aortic aneurysm. The criteria list was developed by the Limburg PAOD research group, which included three general practitioners, a cardiologist, a vascular surgeon, and a neurologist. An end point was categorized as definite when a subject had signs or symptoms corresponding with the disease and supplementary examinations had confirmed the diagnosis. In The Netherlands, the general practitioner receives all correspondence for every patient who is referred to a specialist. This correspondence was attached to the cardiovascular morbidity questionnaire of each participant. All subjects who changed address or general practice during the follow-up period were traced, and documentation was given by the new general practice.
Definitions of nonfatal cardiovascular events
Nonfatal cardiovascular events were defined as follows:
• Minor stroke: Clinical signs and symptoms corresponding with a totally reversible focal disturbance of the cerebral function lasting less than 48 hours, and the general practitioner being present at the time of episode occurrence Cerebrovascular disease comprised minor stroke and stroke; coronary heart disease comprised angina, MI and congestive heart failure; and cardiovascular disease comprised cerebrovascular disease, coronary heart disease, and abdominal aortic aneurysm.
Ascertainment of deaths during the follow-up period
Mortality data were collected by the general practice centers. In The Netherlands, copies of hospital discharge summaries or postmortem findings from all deaths occurring in the hospitals are sent to the general practitioner. The collaborating physicians completed a cardiovascular morbidity and mortality questionnaire for the deceased participants. Data on fatal strokes, MIs, sudden deaths, abdominal aortic aneurysms, and deaths due to PAOD complications were obtained. Deaths due to other cardiovascular and noncardiovascular causes were also reported and coded based on the International Classification of Primary Care (ICPC) [12] . For subjects of whom the date of death was uncertain, the exact date was sought from the municipal registries. To ensure that the protocol criteria were fulfilled, the cardiovascular morbidity and mortality lists were checked by two independent investigators (JH and HS).
Cerebrovascular death comprised fatal strokes; coronary heart disease mortality comprised sudden deaths due to MI, congestive heart failure, atrial fibrillation, and nonrheumatic heart valve disease; cardiovascular mortality comprised cerebrovascular death, coronary heart disease mortality, deaths due to abdominal aortic aneurysm, and complications of PAOD.
Statistical analyses
Baseline measurements between groups were compared using the χ 2 test statistics (for categorical variables) and student's t test (for continuous variables). Total and sex-specific incidence rates for cardiovascular morbidity and mortality were calculated based on person-years at risk (number of events divided by the person-years at risk of the initial population). Morbidity and mortality rates were recalculated to the source population as appropriately weighted means of morbidity and mortality rates per prior risk category. Because of small numbers of observed events, the normal approximation method for confidence intervals (CIs) was not valid, and therefore the method proposed by Waller et al. [13] was used with an adaptation for the assumed Poisson distribution for the numbers of events. Cox proportional hazards analysis was used to determine associations between asymptomatic and symptomatic PAOD versus mortality or nonfatal event-free survival time, adjusted for differences in follow-up time and baseline covariates: age, gender, smoking status, diabetes, hypertension, hypercholesterolemia and the presence of cardiovascular diseases at baseline. Cox models also were run for men and women separately. The hazard ratio (HR) derived from these models is comparable to a RR. Follow-up time was defined from the baseline measurement date to the end-point or end of the study (April 1997).
When more than one event of the same type occurred, only the first of these was counted in the analyses.
Results
Population
At baseline, 314 subjects had asymptomatic PAOD (50.6% female), 138 subjects had symptomatic PAOD (34.1% female), and 6 subjects had PAOD of unspecified type. Table 1 shows the baseline characteristics of the asymptomatic, symptomatic, and non-PAOD subjects. Asymptomatic PAOD subjects and claudicants were significantly older, had a worse risk-factor profile, and more often had a history of other cardiovascular diseases compared with non-PAOD subjects.
After a mean follow-up of 7.2 years, 3070 subjects (51.8% female) with a mean age of 64 years (range 48-85 years) were followed (84.2% of the initial cohort). The remaining group (15.8%) did not respond for two main reasons: refusal to take part (the majority) or being incapable because of severe illness (e.g., Alzheimer disease) or hospitalization. Nonresponders did not significantly differ in age, gender, and risk factor profile from responders except for diabetes, which was more common among nonresponders.
Nonfatal cardiovascular disease and asymptomatic PAOD: incidence rates and prognostic factors
A total of 562 subjects (18.8%) developed cardiovascular diseases, 427 (16.2%) of the non-PAOD subjects and 135 (36.8%) of the subjects with PAOD at baseline. Nonfatal cardiovascular events occurred in 85 (34.7%) of the asymptomatic subjects, in 47 (40.2%) of the claudicants, and in 3 subjects who had PAOD of unspecified type at baseline.
The cardiovascular morbidity rate for asymptomatic PAOD subjects was estimated at 76.8 per 1000 person-years at risk, compared with 13.6 for the non-PAOD population, but the CI for the PAOD group was large ( Table 2 ). The cardiovascular morbidity rate for claudicants could not be calculated because of zero person-years in one stratum (no claudicants present in this prior risk category).
Asymptomatic and symptomatic PAOD were strongly associated with nonfatal events (cerebrovascular and coronary heart disease) after adjustment for other covariates (Table 3) .
Other significant independent predictors of cardiovascular morbidity were increasing age, male gender, hypertension, diabetes, and cardiovascular disease co-morbidity at baseline. The adjusted HR of co-existing cardiovascular disease at baseline for a nonfatal event was 2.5 (95% CI 2.1-2.9).
Total and cause-specific mortality and asymptomatic PAOD: incidence rates and prognostic factors
A total of 481 subjects (13.2%) from the original study population died during the follow-up period: 349 (10.9%) in the non-PAOD group, 81 (25.8%) in the asymptomatic group, and 43 (31.2%) in the symptomatic PAOD group. Two subjects who had PAOD of unspecified type at baseline and six subjects who could not be classified because of a missing ABPI also died during the follow-up period. Much higher total and cardiovascular mortality rates were observed in asymptomatic PAOD subjects (42.8 and 35.8 per 1000 person-years, respectively) compared with non-PAOD subjects (10.9 and 2.4 per 1000 person-years, respectively). Mortality rate estimates for death due to other causes were similar for asymptomatic and non-PAOD (see Table 2 ). Table 2 The Limburg PAOD longitudinal study: morbidity and mortality rates per 1000 person-years at risk for non-PAOD, asymptomatic and overall PAOD at baseline Non-PAOD at baseline (N ϭ 2628) Overall PAOD at baseline (N ϭ 367 a ) Asymptomatic PAOD at baseline (N ϭ 245) Abbreviations: MI, myocardial infarction; PAOD, peripheral arterial occlusive disease. For symptomatic PAOD, no separate incidence rates could be calculated because of lack of data in one of the prior risk strata. a Including five subjects who had PAOD of unspecified type (three developed a nonfatal event, and two died). b Per 1000 person-years (95% CI). c For definitions, see Methods. d For fatal events, the nonresponders were also included in the analyses. e Total number of deaths when non-PAOD and deceased subjects are counted does not add to 481: an additional six subjects died who could not be classified due to missing ABPI, and for one subject the cause of death was unknown.
f Including 11 subjects of whom the cause of death was unknown. g Including six subjects of whom the cause of death was unknown.
Asymptomatic and symptomatic PAOD were significant prognostic factors for total and cardiovascular mortality (see Table 3 ). The increased risk of total mortality in these subjects was mainly due to cardiovascular mortality. The risk of cardiovascular death for asymptomatic PAOD subjects and claudicants was similar. No association was found between death from other causes and asymptomatic or symptomatic PAOD.
Other significant independent predictors of total and cause-specific mortality were increasing age, male gender, smoking, hypertension, diabetes, and cardiovascular disease d For fatal events, the nonresponders were also included in the analyses. e Total number of deaths when non-PAOD and deceased subjects are counted does not add to 481. An additional six subjects died who could not be classified due to missing ABPI, and for one the cause of death was unknown.
co-morbidity at baseline. The adjusted HRs of co-existing cardiovascular disease at baseline for total and cause-specific mortality varied from 1.9 (95% CI 1.6-2.4) for total mortality to 4.1 (95% CI 2.5-5.2) for MI death.
Gender and outcome
The number of asymptomatic PAOD subjects with an adverse event, when stratified by gender, was relatively small, so the power to detect significant differences and associations was low. During the follow-up period, 51 (40.5%) of the men and 34 (28.6%) of the women with asymptomatic PAOD at baseline developed a nonfatal cardiovascular event. Among the male claudicants at baseline, 32 (40.0%) developed a nonfatal cardiovascular event. Among the female claudicants at baseline, 15 (40.5%) developed a nonfatal event. Multivariable analyses showed that asymptomatic PAOD was a stronger predictor for nonfatal MI in female subjects than in male subjects (Table 4) .
Mortality occurred in 51 (33.3%) of the male subjects and in 30 (18.6%) of the female subjects who were asymptomatic at baseline. Among the claudicants at baseline, 31 (34.1%) of the male subjects and 12 (25.5%) of the female subjects died during the follow-up period. Multivariable analyses showed that in male subjects asymptomatic PAOD was a predictor for cardiovascular mortality, stroke in particular (see Table 4 ).
Discussion
Our results show that in the general population, asymptomatic PAOD subjects developed nonfatal and fatal cardiovascular events more often than non-PAOD subjects. Asymptomatic PAOD was not only a significant predictor for nonfatal cardiovascular disease, but also for total and cardiovascular mortality. Asymptomatic and symptomatic PAOD subjects had a comparable prognosis for nonfatal and fatal events. Female asymptomatic PAOD subjects seemed to be at high risk for a nonfatal MI, whereas the risk for fatal stroke is relatively high in male subjects with asymptomatic PAOD.
Major losses to follow-up may form a handicap in cohort studies, introducing selection and survival bias. To restrict Table 4 The Limburg PAOD longitudinal study: gender-specific hazard ratios of outcome after 7.2 years for asymptomatic PAOD subjects at baseline losses to follow-up in our study, subjects who were unable to visit the general practice were offered home visits. Those who missed their appointment were telephoned and invited to attend a second time. We cannot rule out that the nonresponse group might have had a different nonfatal cardiovascular disease incidence, even though quantitatively this should be minimal.
Mortality data could have been missed in the group who could not be traced during the follow-up period, resulting in an underestimation of the mortality rates. Less than 1% of the nonresponders was lost to follow-up because of outmigration or was unknown in the general practice. All the other nonresponders were alive at the time of data collection. Therefore, we are confident that the mortality data are fairly complete. Cause of death was not known for 18 subjects of whom 6 had PAOD at baseline and 1 could not be classified because of missing ABPI. Except for the latter one, these subjects were included in the group of death due to other causes. Thus, there is a possibility of underestimation of the HRs for cardiovascular death.
Nonfatal cardiovascular disease and asymptomatic PAOD: incidence rates and prognostic factors
There are few studies with data on morbidity rates and HRs for asymptomatic PAOD subjects. The Lipid Research Study reported a threefold excess of cardiovascular morbidity among PAOD subjects after 10 years of follow-up [6] . Angina pectoris seemed more frequent in asymptomatic subjects in the Edinburgh Artery study after 5 years of followup [7, 14] . In that study, subjects with an ABPI р0.90 had significantly increased RRs for nonfatal MI and stroke [14] , in accordance with our results. In the Cardiovascular Health Study, 5714 subjects у65 years were followed for 6 years. Among those without prevalent cardiovascular disease at baseline (n ϭ 4268), subjects with an ABPI Ͻ0.9 at baseline had RRs to develop nonfatal events that were similar to our results when adjusted multivariately for co-variables (MI 1.40, angina 1.31, stroke 1.12) [21] .
Total and cause-specific mortality and asymptomatic PAOD: incidence rates and prognostic factors
Our mortality rate estimates for overall PAOD are in accordance with those reported in other studies [15] [16] [17] . Only two prospective population-based studies explicitly addressed RRs for mortality in asymptomatic PAOD subjects [7, 15] . The Lipid Research Study presented significant adjusted RRs for total, cardiovascular, and coronary heart disease mortality in asymptomatic PAOD subjects with no evidence of CVD at baseline, which is concordant with our findings [15] . In that study, compared with asymptomatic PAOD subjects, claudicants had a worse prognosis with regard to mortality. Our observations were similar to those of the Edinburgh Artery study [7, 14] . This 5-year prospective follow-up study showed that subjects with asymptomatic disease had a worse total (and cardiovascular) mortality (RR 2.4 and 2.1, respectively) compared with non-PAOD subjects. These RRs, however, were only adjusted for age. In addition, no substantially higher mortality RRs for claudicants compared with the asymptomatic PAOD subjects were presented in that study. Leng et al [14] also reported that subjects with an ABPI р0.90 were at significantly elevated risk for total and cardiovascular mortality, the RRS being 1.6 and 1.9, respectively, after adjustments for age, gender, diabetes, MI, and angina pectoris at baseline were made [14] . Like our results, in the Edinburgh Artery Study, PAOD was not associated with death due to other causes [14] . In the Cardiovascular Health Study among patients without CVD at baseline, the RRs for total and CVD mortality were somewhat higher (1.62 and 2.03, respectively) as compared with our results [21] .
Gender
In the Lipid Research Study, women with PAOD developed more nonfatal cardiovascular events than men [6] , and men with PAOD had higher cardiovascular mortality rates than women [15] . We did not observe higher cardiovascular morbidity rates in female PAOD subjects compared with male PAOD subjects. However, in asymptomatic women, we found a higher risk for nonfatal MI.
Male PAOD subjects (asymptomatic and symptomatic) are consistently at high risk for cardiovascular death in several population-based follow-up studies [16] [17] [18] 21] . The Israeli Ischemic Heart Disease Project reported a strong and independent association between new onset of intermittent claudication and stroke in male claudicants after 21 years of follow-up [19] . Increased RR for fatal strokes in male claudicants was also reported in the Whitehall Study [16] . We also demonstrated significant associations of PAOD and fatal stroke in (asymptomatic) male subjects compared with female subjects. Male PAOD subjects are at particular risk for cerebrovascular mortality.
Clinical implications
Atherosclerosis is a generalized disease, and therefore subjects with asymptomatic or symptomatic PAOD are at high risk of developing fatal and nonfatal cardiovascular diseases. As shown in this study, co-existing coronary or cerebrovascular disease at baseline is a significant prognostic factor for nonfatal cardiovascular events and death. When we excluded this covariate from the analyses, asymptomatic and symptomatic PAOD, being indicators of cardiovascular status as well, became even stronger prognostic factors.
In general, asymptomatic PAOD subjects are younger than symptomatic PAOD subjects [1] , justifying preventive measures in an early stage. Case finding in high-risk groups is appropriate: Atherosclerotic risk factors such as diabetes, hypercholesterolemia, and hypertension can and should be treated adequately, and smoking should be strongly advised against. Our results emphasize the prognostic implications of a reduced ABPI measurement (ABPI Ͻ 0.95) in high-risk subjects. Given the diagnostic validity shown in earlier studies [8, 9, 20] and the prognostic implications shown by this study and those of other groups, we might conclude that measuring the ABPI is appropriate in a primary health care setting, providing valuable information concerning an individual's present and future cardiovascular disease status.
